Abiopharma

(85% Positive) Recursion Pharmaceuticals Inc (RXRX) Files Form 8-K

(85% Positive) ADMA Biologics Inc (ADMA) Reports Q1 2026 Financial Results

(10% Negative) Harmony Biosciences (HRMY) Announces Delay in Trials Trials for San Francisco Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

(99% Positive) Perspective Therapeutics Inc (CATX) Announces Enrollment Update for treatments Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

(85% Positive) Fulcrum Therapeutics (FULC) Files Form 8-K

(99% Positive) Bionano Genomics Inc (BNGO) Reports Q1 2026 Financial Results

(99% Positive) Adaptive Biotechnologies (ADPT) Reports Q1 2026 Financial Results

(90% Positive) Rigel Pharmaceuticals Inc (RIGL) Announces Enrollment Update for year Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

(10% Negative) Twist Bioscience (TWST) Reports Q1 2026 Financial Results

(99% Neutral) Progyny Inc (PGNY) Reports Q1 2026 Financial Results

New Form 3 - ACHIEVE LIFE SCIENCES, INC. Filed: 2026-01-12 AccNo: 0001193125-26-009831 Size: 20 KB

(80% Positive) CVRx Inc. (CVRX) Reports Q1 2026 Financial Results

Mereo BioPharma Provides Corporate Update

TransMedics Announces New Global Headquarters and Expansion at Assembly Innovation Park in Somerville, Massachusetts

(10% Negative) Mereo BioPharma (MREO) Announces Delay in setrusumab Trials for osteogenesis imperfecta Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment